Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors
July 03 2019 - 4:01PM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led
biopharmaceutical company focused on immuno-inflammatory and
dermatological diseases, today announced the appointment of Maxine
Gowen to its board of directors, effective July 2, 2019.
Dr. Gowen founded Trevena, Inc. and served as its President and
Chief Executive Officer from 2007 until October 2018. Prior to
this, Dr. Gowen held a variety of leadership roles at
GlaxoSmithKline (GSK) over a period of fifteen years. As Senior
Vice President for the Center of Excellence for External Drug
Discovery (CEEDD), she developed an innovative new approach to
externalizing drug discovery in big pharma. Dr. Gowen was
previously President and Managing Partner at SR One, the venture
capital subsidiary of GSK, where she led its investments in, and
served on the board of directors of, numerous companies. Until
2002, Dr. Gowen was Vice President, Drug Discovery, Musculoskeletal
Diseases at GSK, responsible for drug discovery and early
development for osteoporosis, arthritis, and metastatic bone
disease. Dr. Gowen held a tenured academic position in the School
of Pharmacology, University of Bath, UK from 1989 to 1992. Dr.
Gowen graduated with a B.Sc. in biochemistry from the University of
Bristol, UK, then received a Ph.D. in cell biology from the
University of Sheffield, UK, and received an MBA from the Wharton
School of the University of Pennsylvania. She currently serves on
the board of Akebia Therapeutics, Inc. since July 2014 and Idera
Pharmaceuticals, Inc. since January 2016, both public
biopharmaceutical companies, and on the board of the state
biotechnology industry association, Life Sciences PA. Dr.
Gowen also served on the board of the national biotechnology
industry association, BIO, from 2008 to 2018.
“I'd like to take this opportunity to welcome our new board
member, Maxine Gowen, who will serve as an independent
director. Her extensive operational and development
experience will be an invaluable asset for Aclaris as we continue
to develop our pipeline," said Dr. Neal Walker, President and Chief
Executive Officer of Aclaris.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a physician-led biopharmaceutical
company committed to addressing the needs of people with
immuno-inflammatory and dermatological diseases who lack
satisfactory treatment options. The company’s diverse and
multi-stage portfolio includes two FDA-approved medicines, one
late-stage investigational medicine, and a pipeline powered by a
robust R&D engine exploring protein kinase regulation. Aclaris
Therapeutics’ active development programs focus on areas where
significant treatment gaps exist, such as common warts, alopecia
areata, and vitiligo. For additional information, please visit
www.aclaristx.com and follow Aclaris on LinkedIn or Twitter
@aclaristx.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
"believe," "expect," "may," "plan," "potential," "will," and
similar expressions, and are based on Aclaris’ current beliefs and
expectations. These forward-looking statements include expectations
regarding the development of Aclaris’ pipeline. These statements
involve risks and uncertainties that could cause actual results to
differ materially from those reflected in such statements. Risks
and uncertainties that may cause actual results to differ
materially include uncertainties inherent in the conduct of
clinical trials and in commercialization of products, Aclaris’
reliance on third parties over which it may not always have full
control, and other risks and uncertainties that are described in
the Risk Factors section of Aclaris’ Annual Report on Form 10-K for
the year ended December 31, 2018, and other filings Aclaris makes
with the U.S. Securities and Exchange Commission from time to time.
These documents are available under the "SEC filings” section of
the Investors page of Aclaris’ website at http://www.aclaristx.com.
Any forward-looking statements speak only as of the date of this
press release and are based on information available to Aclaris as
of the date of this release, and Aclaris assumes no obligation to,
and does not intend to, update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:Aclaris ContactMichael Tung, M.D.Senior
Vice President Corporate Strategy/Investor
Relations484-329-2140mtung@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Sep 2023 to Sep 2024